NEW YORK, Sept. 23 (GenomeWeb News) - Gene Logic said that it has lowered its revenue guidance for 2003 to a range of $72 million to $76 million, on a pro forma basis.

In late July, Gene Logic had said it was expecting its pro forma revenues for the year to be between $80 million to $84 million.

Gene Logic said that the pro forma results assume that the company's April 1 acquisition of TherImmune took place on January 1. Actual revenues for the year are expected to be in the range of $65 million to $69 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.